Abstract
Abnormal platelet reactivity has been linked to unstable angina, myocardial infarction, post angioplasty stenosis, cerebral ischemia, thrombotic stroke and a variety of inflammatory vascular disorders associated with transplantation. Drugs that inhibit blood coagulation, promote fibrinolysis or block platelet activation are important therapeutic agents in cardiovascular medicine. However, many of the current antiplatelet modalities are nonspecific, ineffective or associated with severe side effects that limit their usefulness. In this article, we discuss some basic aspects of platelet pathophysiology to illustrate the importance of ADP stimulation and signaling in platelet activation. CD39, the ATP diphosphohydrolase (ATPDase) expressed on quiescent vascular endothelium, modulates platelet purinoreceptor activity by the sequential hydrolysis of extracellular ATP or ADP directly to AMP. This thromboregulatory potential of CD39 has been recently demonstrated by the generation of mutant mice with disruption of the gene, and by a series of experiments where high level ATPDase expression has been attained by adenoviral vectors in the injured vasculature. Systemic administration of soluble derivatives of CD39 or targeted expression of the native protein to sites of vascular injury may have future therapeutic application.
Keywords: Anti-Platelet Therapies, CD39/Vascular ATP Diphosphohydrolase, Thrombotic Disorders, CD39, Hemostasis, Platelets, Integrins, Vascular Throm Bosis, Antiplatelet drugs
Current Drug Targets
Title: New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders
Volume: 1 Issue: 3
Author(s): Imrana Qawi and Simon C. Robson
Affiliation:
Keywords: Anti-Platelet Therapies, CD39/Vascular ATP Diphosphohydrolase, Thrombotic Disorders, CD39, Hemostasis, Platelets, Integrins, Vascular Throm Bosis, Antiplatelet drugs
Abstract: Abnormal platelet reactivity has been linked to unstable angina, myocardial infarction, post angioplasty stenosis, cerebral ischemia, thrombotic stroke and a variety of inflammatory vascular disorders associated with transplantation. Drugs that inhibit blood coagulation, promote fibrinolysis or block platelet activation are important therapeutic agents in cardiovascular medicine. However, many of the current antiplatelet modalities are nonspecific, ineffective or associated with severe side effects that limit their usefulness. In this article, we discuss some basic aspects of platelet pathophysiology to illustrate the importance of ADP stimulation and signaling in platelet activation. CD39, the ATP diphosphohydrolase (ATPDase) expressed on quiescent vascular endothelium, modulates platelet purinoreceptor activity by the sequential hydrolysis of extracellular ATP or ADP directly to AMP. This thromboregulatory potential of CD39 has been recently demonstrated by the generation of mutant mice with disruption of the gene, and by a series of experiments where high level ATPDase expression has been attained by adenoviral vectors in the injured vasculature. Systemic administration of soluble derivatives of CD39 or targeted expression of the native protein to sites of vascular injury may have future therapeutic application.
Export Options
About this article
Cite this article as:
Qawi Imrana and Robson C. Simon, New Developments in Anti-Platelet Therapies Potential Use of CD39/Vascular ATP Diphosphohydrolase in Thrombotic Disorders, Current Drug Targets 2000; 1 (3) . https://dx.doi.org/10.2174/1389450003349173
DOI https://dx.doi.org/10.2174/1389450003349173 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Molecular Targets Associated with Ethanol Toxicity and Implications in Drug Development
Current Pharmaceutical Design Innate Immune Inflammatory Response in the Acutely Ischemic Myocardium
Medicinal Chemistry The Role of Endothelin-1 in Obstructive Sleep Apnea Syndrome and Pulmonary Arterial Hypertension: Pathogenesis and Endothelin-1 Antagonists
Current Medicinal Chemistry A Review of Gene Expression Profiling of Human Embryonic Stem Cell Lines and their Differentiated Progeny
Current Stem Cell Research & Therapy Role of Galectins in Allergic Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Different Lifestyles in Young Women From Urban and Rural Areas May Explain Different Cardiovascular Risk
Vascular Disease Prevention (Discontinued) Ximelagatran - A Promising New Drug in Thromboembolic Disorders
Current Pharmaceutical Design Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Molecular Targets of Diabetic Cardiovascular Complications
Current Drug Targets Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies
Current Diabetes Reviews Psychological Treatments for Cognitive Dysfunction in Major Depressive Disorder: Current Evidence and Perspectives<sup>§</sup>
CNS & Neurological Disorders - Drug Targets Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry Antioxidant Activity of Resveratrol Analogs
Letters in Drug Design & Discovery Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?
Current Vascular Pharmacology Alterations in Homocysteine Metabolism Among Alcohol Dependent Patients - Clinical, Pathobiochemical and Genetic Aspects
Current Drug Abuse Reviews LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk
Current Molecular Pharmacology